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Abstract
Objective: TLR4 plays an important role in the pathogenesis of Guillain-Barre
syndrome (GBS). The relationships between TLR4 polymorphisms and suscepti-
bility to GBS are poorly understood. We investigated the frequency and
assessed the association of two single nucleotide polymorphisms (SNPs) in the
extracellular domain of TLR4 (Asp299Gly and Thr399Ile) with disease suscepti-
bility and the clinical features of GBS in a Bangladeshi cohort. Methods: A total
of 290 subjects were included in this study: 141 patients with GBS and 149
unrelated healthy controls. The TLR4 polymorphisms Asp299Gly and Thr399Ile
were genotyped using polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) assay. Results: The minor 299Gly allele was signifi-
cantly associated with GBS susceptibility (P = 0.0137, OR = 1.97, 95%
CI = 1.17–3.31), and was present at a significantly higher frequency in patients
with the acute motor axonal neuropathy (AMAN) subtype of GBS (P = 0.0120,
OR = 2.37, 95% CI = 1.26–4.47) than acute inflammatory demyelinating
polyneuropathy (AIDP) subtype (P = 0.961, OR = 1.15, 95% CI = 0.38–3.48);
when compared to healthy controls. The genotype frequency of the Asp299Gly
polymorphism was not significantly different between patients with GBS and
healthy controls. The Asp299-Thr399 haplotype was associated with a signifi-
cantly lower risk of developing GBS (P = 0.0451, OR = 0.63, 95% CI = 0.40–
0.99). No association was observed between the Thr399Ile polymorphism and
GBS disease susceptibility. Interpretation: The TLR4 minor 299Gly allele was
associated with increased susceptibility to GBS and the axonal GBS subtype in
the Bangladeshi population. However, no associations were observed between
the genotypes of the Asp299Gly and Thr399Ile SNPs and antecedent C. jejuni
infection or disease severity in Bangladeshi patients with GBS.
Introduction
The potentially life-threatening immune-mediated polyneu-
ropathy Guillain-Barre syndrome (GBS) is frequently pre-
ceded by an infection that induces an aberrant autoimmune
response targeting the peripheral nervous system (PNS).1,2
Several infections have been associated with the pathogenesis
of GBS. Campylobacter jejuni is the most frequent antecedent
infection in GBS,1 and molecular mimicry between C. jejuni
lipopolysaccharides (LPS) and host nerve gangliosides can
trigger GBS.3 However, only a very small proportion of
C. jejuni-infected patients develop GBS, and the molecular
mechanisms that trigger autoreactivity are still poorly under-
stood.4 In addition to C. jejuni infection, the enthusiasm for
investigation of host genetic factors involved in predisposi-
tion to disease has led to the identification of substantial roles
for several polymorphisms in genes linked to immunogenic-
ity. Several genetic polymorphisms are significantly associated
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with the development of GBS. IL10 gene polymorphisms are
significantly more frequent among patients with GBS than
healthy controls.5 Furthermore, a few genetic polymorphisms
in genes encoding inflammatory mediators were significantly
associated with higher risk of GBS disease in Bangladeshi
population,6,7 which raises the question of whether the toll-
like receptor-4 (TLR4) gene polymorphism also contribute to
autoimmune diseases such as GBS.
The roles of the toll-like receptor (TLR) genes in
autoimmune diseases have attracted significant attention.
TLR4 serves as the signal-transducing receptor in response
to bacterial LPS binding to host cells and initiates cyto-
kine and chemokine production cascades that trigger the
host immune system to protect against microbial inva-
sion.8–10 The polymorphic spectrum of the TLR4 gene has
been elucidated. Two co-segregating non-synonymous
polymorphisms occur in the region encoding the extracel-
lular domain of TLR4.11 An A?G base transition occurs
at nucleotide +896 (rs4986790), resulting in the exchange
of aspartic acid to glycine at amino-acid position 299
(Asp299Gly). Moreover, a C?T transition at the +1196
position (rs4986791) causes substitution of threonine to
isoleucine at amino acid position 399 (Thr399Ile).11 Both
of these substitutions alter the ligand-binding site of the
receptor.12 Therefore, these SNPs may possibly influence
the response of TLR4 to LPS and render cells hyper-sus-
ceptible to infection by gram-negative bacteria.13,14
Indeed, individuals with Asp299Gly or Thr399Ile TLR4
polymorphisms exhibit blunted responses to bacterial
LPS,15 which may be a consequence of conformational
changes in the extracellular domain of TLR4.16
Very few studies have been conducted for identifying
TLR4 SNPs and its association with susceptibility to GBS.
Indian patients with GBS had a higher prevalence of the
Asp299Gly polymorphism compared to healthy controls.17
However, a similar association between the Asp299Gly poly-
morphism and GBS susceptibility was not observed in a
Dutch population.18 A high prevalence of the Asp299Gly
polymorphism was observed in African children,19 whereas
this SNP was relatively rare in several Asian ethnic popula-
tions.20,21 The variations in the prevalence of TLR4 genotypes
in different populations suggest particular local infectious
pressure and subsequent susceptibility to gram-negative
infection in particular regions. Bangladesh has a high burden
of C. jejuni infection and the clinical phenotype of patients
with GBS from this country is quite severe.22
To improve our understanding of the correlation
between TLR4 polymorphisms and the clinical manifesta-
tion of GBS, we determined the genotype and allele
frequencies of the TLR4 Asp299Gly and Thr399Ile poly-
morphisms in the Bangladeshi population and assessed
the association of these polymorphisms with disease
susceptibility and the clinical characteristics of GBS.
Methods and Materials
Study participants
The study cohort consisted of 300 individuals who were
prospectively enrolled at Dhaka Medical College and
Hospital (DMCH) between 2010 and 2013: 150 patients
with GBS, and 150 healthy individuals with no history
of neurological or chronic medical illnesses who were
genetically unrelated to the patients with GBS. Subse-
quently, nine patients with GBS and one healthy con-
trol were excluded from the study due to poor quality
of DNA samples. Finally, data for 141 patients with
GBS and 149 healthy individuals was included in the
analysis.
Socio-demographic and clinical data and
ethical consideration
The clinical diagnosis for GBS was confirmed using the
criteria defined by the National Institute of Neurological
Disorders and Stroke (NINDS) and further classified
on the basis of electrophysiological criteria into various
subtypes: axonal [acute motor axonal neuropathy
(AMAN) and acute motor sensory axonal neuropathy
(AMSAN)], demyelinating [acute inflammatory demyeli-
nating polyneuropathy (AIDP)] and unclassified (inex-
citable nerves, and equivocal).23,24 Disease severity was
defined using the Medical Research Council (MRC)-sum-
score at entry and disease outcome was assessed using the
GBS disability scale (GBS-DS) after six months follow-up.
Patients with a MRC sum score < 40 were defined as
severely affected and 40–60, mildly affected. At 6 months
follow-up, good outcome was defined as able to walk
independently (GBS-DS of 1 or 2) and poor outcome as
unable to walk independently (GBS-DS of 3, 4, or 5).17,18
This study was reviewed and approved by the ethical
committee of both the DMCH and icddr,b and writ-
ten informed consent was obtained from all enrolled
participants.
Isolation of genomic DNA
Genomic DNA was extracted from whole blood collected
in lithium heparin coated anti-coagulation blood collec-
tion tubes. The QIAamp DNA Blood Midi Kit (Qiagen,
Hilden, Germany) was used to isolate genomic DNA
according to the manufacturer’s instructions. DNA sam-
ples were dissolved in 19 TE buffer (10 mmol/L Tris-
HCl, 1 mmol/L EDTA, pH 8.0) and stored at 80°C.
Before SNP detection, genomic DNA was diluted in
Milli-Q water to the working concentration (10 ng/lL)
and stored at 20°C.
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Determination of TLR4 (Asp299Gly and
Thr399Ile) genotypes
The TLR4 allelic variants Asp299Gly (rs4986790) and
Thr399Ile (rs4986791) were genotyped using a mis-
matched polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) assay, as previously
described.25 The forward primers were specially designed to
introduce a restriction enzyme recognition site. The regions
encoding the Asp299Gly and Thr399Ile positions were
amplified using published primer sequences and amplifica-
tion profiles.17,25 Primer for TLR4 Asp299Gly were forward
50-GATTAGCATACTTAGACTA-CTACCTCCATG-30, rev
erse 50-GATCAACTTCTGAAAAA-GCATTCCCAC-30, and
for TLR4 Thr399Ile were forward 50-GGTTGCTGTTCT
CAAAGTGATTTTGGGAGAA-30, reverse 50-ACCTGAA-
GACTGGAGAGTGAGTTAAATGCT-30. The PCR products
were subjected to restriction digestion with the respective
restriction endonucleases, NcoI for +A896G & HinfI for
+C1196T. The digested fragments were separated on 3%
agarose gel and visualized by ethidium bromide staining.
Serological assays
Serological tests were performed on the pretreatment
serum of patients with GBS to assess anti-ganglioside anti-
bodies and antecedent C. jejuni infection. Enzyme-linked
immunosorbent assay (ELISA) was used to detect IgG, IgM
and IgA antibodies against C. jejuni and IgG against the
nerve GM1-ganglioside, as described previously.26,27
Statistical analysis
Hardy–Weinberg equilibrium was assessed for control group
using the Chi-square test. Associations of the TLR4 SNPs
with disease susceptibility and clinical features of GBS were
assessed by Fisher’s exact test and interpreted with odds
ratios (OR) and 95% confidence intervals (CI); P-values ≤
0.05 were considered significant. All statistical tests were
adjusted using the Bonferroni correction to exclude type I
errors. Haplotype analysis was performed to assess the asso-
ciations of haplotypes between two groups using SHEsis
software (http://analysis.bio-x.cn/myAnalysis.php). Haplo-
types with a frequency < 0.03 were ignored in the analysis.28
Statistical analyses were performed using Graph Pad Prism
(version 5.01; GraphPad Software, Inc., La Jolla, CA, USA)
and SPSS (16.0 version, Chicago, IL, USA).
Results
Study population
The median age, 141 patients with GBS was 28 years
(range, 4 to 75-years-old) and 149 healthy controls were
34 years (range, 17 to 75-years-old). Overall, 88% (124/
141) of patients with GBS reported antecedent symptoms:
diarrhea (58%; 72/124) was the leading antecedent symp-
tom, followed by respiratory tract infections (21%; 26/
124), and fever (11%; 14/124). More than two-thirds
(70%; 99/141) of patients were severely affected with
GBS, 60% (61/101) of cases were classified as the axonal
variant and 41% (58/141) were anti-ganglioside (GM1)
antibody positive (Table 1).
The TLR4 Asp299Gly polymorphism is
associated with susceptibility to GBS
The associations between the Asp299Gly and Thr399Ile
genotypes and the risk of GBS are shown in Table 2.
Genotype of TLR4 Asp299Gly polymorphism was
not associated with increased susceptibility to GBS
(P = 0.5387, OR = 1.26, 95% CI = 0.69–2.31). The
Gly299Gly genotype was detected in eight of the 141
(6%) patients with GBS, but not in any of the 149 healthy
controls. The minor 299Gly allele was significantly associ-
ated with susceptibility to GBS (P = 0.0137, OR = 1.97,
Table 1. Demographic and clinical features of the healthy controls
and patients with GBS.
Features
Healthy controls
n = 149 (%)
Patients with GBS
n = 141 (%)
Sex
Male:female (%) 52:77 (35/52) 103: 38 (73/27)
Age
Median age, years (range) 34 (17–75) 28 (4–75)
Area of residence
Rural – 86 (61)
Urban – 55 (39)
Antecedent events
Total – 124 (88)
Diarrhea – 72 (58)
Respiratory infection – 26 (21)
Fever – 14 (11)
Other – 15 (12)
Severity based on MRC sum score
Severely affected (<40) – 99 (70)
Mildly affected (40–60) – 42 (30)
Anti-ganglioside antibodies
GM1-positive 3 (2) 58 (41)
GM1-negative 146 (98) 83 (59)
GBS subtype (n = 101)
AMAN – 56 (55)
AMSAN – 5 (5)
AIDP – 21 (21)
Unclassified – 14 (14)
AMAN, acute motor axonal neuropathy; AMSAN, acute motor-sen-
sory axonal neuropathy; AIDP, acute inflammatory demyelinating
polyneuropathy.
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95% CI = 1.17–3.31); this effect remained statistically sig-
nificant after Bonferroni adjustment (P = 0.0137/
2 = 0.0069). The genotype (P = 0.6507, OR = 1.19, 95%
CI = 0.66–2.16) and allele frequencies (P = 0.3332,
OR = 1.34, 95% CI = 0.78–2.31) of the Thr399Ile poly-
morphism was homogenously distributed between
patients with GBS and healthy controls (Table 2).
The TLR4 Asp299Gly polymorphism is
associated with the axonal subtype of GBS
The genotype and allele frequencies of the Asp299Gly and
Thr399Ile SNPs were compared between subgroups of
patients with different clinical subtypes of GBS and
healthy controls. The Gly299Gly genotype was present at
a higher frequency among patients with the axonal
variant (AMAN) of GBS than the demyelinating variant
and healthy controls. Allele disparity was also observed
between patients with different subtypes of GBS and
healthy controls. The allele frequency of the 299Gly allele
in the subgroup of patients with the AMAN subtype was
double that of healthy controls and the 299Gly allele was
significantly associated with the axonal variant of GBS
(P = 0.0120, OR = 2.37, 95% CI = 1.26–4.47; Table 3).
The genotype and allele frequencies of the TLR4
Thr399Ile polymorphism were not significantly associated
with the electrophysiological subtypes when compared to
healthy control. The frequency of the 399Ile allele was
higher among patients with the axonal subtype of GBS
compared to healthy controls (15% vs. 9%; Table 3),
though this difference was not significantly associated
(P = 0.070, OR = 1.87, 95% CI = 0.97–3.60).
Table 2. Genotype and allele distributions of the Asp299Gly and Thr399Ile TLR4 polymorphisms among patients with GBS and healthy controls.
TLR4 SNPs
GBS Healthy controls
P-value OR (95% CI)n = 141 Frequency n = 149 Frequency
TLR4 genotypes
Asp299Asp 106 0.752 124 0.832 – Reference
Asp299Gly 27 0.191 25 0.168 0.5387 1.26 (0.69–2.31)
Gly299Gly 8 0.057 0 0.000 NC NC
Thr399Thr 111 0.787 123 0.826 – Reference
Thr399Ile 28 0.199 26 0.174 0.6507 1.19 (0.66-2.16)
Ile399Ile 2 0.014 0 0.0 NC NC
TLR4 alleles
Asp Allele 239 0.848 273 0.916 – Reference
Gly Allele 43 0.152 25 0.084 0.01371 1.97 (1.17–3.31)
Thr Allele 250 0.887 272 0.913 – Reference
Ile Allele 32 0.113 26 0.087 0.3332 1.34 (0.78–2.31)
Bonferroni-adjusted significance threshold was 0.0167 for genotypes and 0.025 for alleles.
NC, not calculated.
1Statistically significant
Table 3. Association between the Asp299Gly and Thr399Ile TLR4 SNPs and GBS subtypes.
TLR4
Polymorphism
Subtype AMAN vs. controls AIDP versus controls
AMAN
n = 56 (%)
AIDP
n = 21 (%)
Control
n = 149 (%) P-value OR P-value OR
Asp299Asp 40 (72) 17 (81) 124 (83) – Reference – Reference
Asp299Gly 12 (21) 4 (19) 25 (17) 0.3073a 1.49 (0.69–3.23) 0.959a 1.17 (0.36–3.77)
Gly299Gly 4 (7) 0 (0) 0 (0) NC NC NC NC
Asp Allele 92 (82) 38 (90) 273 (91) – Reference – Reference
Gly Allele 20 (18) 4 (10) 25 (9) 0.0120a1 2.37 (1.26-4.47) 0.961b 1.15 (0.38–3.48)
Thr399Thr 40 (72) 17 (81) 123 (82) – Reference – Reference
Thr399Ile 15 (27) 4 (19) 26 (17) 0.1670a 1.77 (0.86–3.68) 0.8998b 1.11 (0.35–3.58)
Ile399Ile 1 (1) 0 (0) 0 (1) NC NC NC NC
Thr Allele 95 (85) 38 (90) 272 (91) – Reference –
Ile Allele 17 (15) 4 (10) 26 (9) 0.070a 1.87 (0.97–3.60) 0.905b 1.10 (0.36–3.33)
‘a’ Fisher’s exact test; ‘b’ Yates correction; 1statistically significant; OR, odds ratio with 95% confidence interval; NC, not calculated.
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No significant association between TLR4
SNPs and the clinical and serological
features of GBS
The patients with GBS were classified into subgroups
based on their clinical and serological characteristics. The
frequencies of the dominant (reference) allele and minor
alleles of the Asp299Gly and Thr399Ile SNPs were not sig-
nificantly different between C. jejuni seropositive and
seronegative patients with GBS, anti-GM1-Ab seropositive
and seronegative patients, severely affected and mildly
affected patients, or patients with good and poor out-
comes at 6-months (Table 4).
TLR4 haplotype analysis for patients with
GBS and healthy controls
The frequency of the Asp299-Thr399 haplotype was sig-
nificantly higher among healthy controls than patients
with GBS (P = 0.0451, OR = 0.63, 95% CI = 0.40–0.99),
though this effect was not significant after Bonferroni
adjustment. The frequencies of the Gly299-Thr399 (0.073
vs. 0.039) and Gly299-Ile399 (0.080 vs. 0.045) haplotypes
were slightly higher among patients with GBS than
healthy controls, but these differences were not significant
(Table 5).
Discussion
TLR4 recognizes LPS and is an important mediator of the
inflammatory response in the first line of host defense.29
The primary aim of this study was to investigate the
association between TLR4 polymorphisms (Asp299Gly
and Thr399Ile) and susceptibility to GBS in the Banglade-
shi population. The minor 299Gly allele of the TLR4
Asp299Gly polymorphism was associated with signifi-
cantly higher susceptibility to GBS in our population.
However, no associations were found between the
Asp299Gly and Thr399Ile SNPs and the clinical features
of GBS.
Previous studies have assessed immunogenetic risk fac-
tors for GBS among Indian and Dutch populations.17,18
The homozygous TLR4 Gly299Gly genotype was signifi-
cantly associated with susceptibility to GBS in the Indian
study.17 However, while the Dutch cohort included a lar-
ger number of patients (n = 242), no associations were
observed between TLR4 polymorphisms and susceptibility
to GBS.18 In agreement with the Dutch study, we did not
observe any significant difference in the genotype frequen-
cies of the Asp299Gly and Thr399Ile SNPs between the
patients with GBS and healthy controls. However, we
found the minor 299Gly allele of TLR4 was associated sig-
nificantly with an increased risk of GBS. One explanation
for these disparities between studies could be variations
in host response in terms of varied susceptibility of popu-
lations in different regions of the world to pathogenic
infections. In addition, polymorphisms in the extracellular
domain of TLR4 may alter the ability of the host to
respond to environmental stress.15 Thus, our findings
provide evidence that the minor TLR4 299Gly allele might
be a potential immunogenetic factor for GBS and may
contribute to differences in disease susceptibility to vari-
ous infections, including C. jejuni. Previous findings sug-
gested a heterogeneous pattern of TLR4 Asp299Gly and
Table 4. Association between the Asp299Gly and Thr399Ile TLR4 polymorphisms and the clinical characteristics of GBS.
Variable
Reference
Allele/risk allele Allele distribution Odds Ratio 95% CI P-value
Disease severity
Severe (n = 99)/Mild (n = 42)
299Asp 168/71 1.025 0.505–2.080 0.945
299Gly 30/13
399Thr 176/74 1.081 0.488–2.395 0.848
399Ile 22/10
Outcome at 6 months
Poor (n = 19)/Good (n = 111)
299Asp 31/189 0.773 0.314–1.901 0.575
299Gly 7/33
399Thr 35/195 1.615 0.465–5.615 0.447
399Ile 3/27
Anti-GM1-Ab
Positive (n = 58)/Negative (n = 83)
299Asp 95/144 0.691 0.360–1.326 0.423
299Gly 21/22
399Thr 99/151 0.578 0.276–1.211 0.232
399Ile 17/15
C. jejuni infection
Positive (n = 86)/Negative (n = 55)
299Asp 144/95 0.841 0.427–1.658 0.617
299Gly 28/15
399Thr 148/102 0.500 0.216–1.157 0.100
399Ile 24/8
95% CI, 95% confidence interval; MRC sum score: < 40, severely affected; 40–60, mildly affected.
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Thr399Ile polymorphisms (either alone or in combina-
tion) among different ethnic groups in Iran.30
Evidences suggest that systemically and locally released
cytokines and their contribution in immune-mediated of
peripheral nerves damage are important in the pathogene-
sis of GBS.31 The TLR4 Asp299Gly polymorphism has
been shown to result in improper activation of dendritic
cells via the CD14–TLR4 complex and enhances the
stimulation of activated T cells to release elevated levels
of chemokines and proinflammatory cytokines that
induce nerve damage.15 High TLR2 protein expression is
observed in inflamed nerve tissues and TLR4 and TLR9
were upregulated during disease progression in a rat
model of experimental autoimmune neuritis (EAN).32,33
Our findings indicate an association between the TLR4
299Gly allele and axonal damage in patients with GBS, as
previously reported in an Indian population,17 but not
in a European population.18 One possible explanation
behind these discrepancies could be the higher prevalence
of the axonal variant of GBS in patients from Asian coun-
tries than Europe.
Several reports have described an association between
TLR4 polymorphisms and an attenuated blunted immune
response towards LPS.15 Individuals with the Asp299Gly
polymorphism may exhibit modified cellular responses;
changes in the rotation and charge of the ligand (LPS)
docking site may affect the interaction between LPS and
the TLR4 receptor.12 Indeed, the Asp299Gly polymor-
phism was related to an increased risk of gram-negative
infections,16 which may be associated with elevated TNF-
a production.11 Elevated production of the proinflamma-
tory cytokine TNF-a may stimulate the inflammatory cells
of the innate immune system and enhance the risk of
GBS.11 However, the exact mechanism by which TLR4
SNPs affect the humoral immune response to C. jejuni
in patients with GBS is unknown. In GBS, C. jejuni
lipooligosaccharides (LOS) trigger the production of
cross-reactive antibodies to peripheral nerve gangliosides.
Structural changes in TLR4 induced by SNPs may reduce
the ability of the host to eliminate bacterial components.
However, we observed no significant associations between
the TLR4 polymorphisms and C. jejuni infection, gan-
glioside mimicry or GBS disease severity.
Previous studies of TLR4 SNPs and co-segregation of
TLR4 genotypes in various populations have reported sig-
nificant associations between TLR4 polymorphisms and
several inflammatory diseases, including rheumatoid
arthritis, malaria, septic shock, and urinary tract infec-
tion.34–37 However, other studies reported no significant
relationships between these SNPs and disease pathogene-
sis.38,39 The TLR4 SNPs are associated with increased risk
of developing septic shock and urinary tract infection.36,37
However, polymorphisms in the TLR4 gene were associ-
ated with a reduced prevalence of diabetic neuropathy in
type 2 diabetes.40
One of the limitations of this study was the moderate
sample size, particularly for the genotype analysis of
patients with GBS and healthy controls. Furthermore, at
the time of enrolment and hospital admission, most
patients (~70%) were severely affected (disability scale of
3 to 5) and almost 80% of patients had improved by 6
months follow-up (disability scale of ≤ 2), which may
have limited our ability to detect an association between
TLR4 SNPs and clinical outcome.
In conclusion, we explored the contribution of the
Asp299Gly and Thr399Ile TLR4 polymorphisms to the
development of GBS in the Bangladeshi population, and
found the minor 299Gly allele was associated with
increased susceptibility to GBS. However, the genotypes
of TLR4 SNPs appear to have no significant influence on
the clinical manifestation of GBS. Additional data on
populations with different ethnicities needs to be obtained
to fully understand the effect of TLR4 polymorphisms on
the pathogenesis and severity of GBS.
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